Daniel Barber Sells 91,343 Shares of Aquestive Therapeutics (NASDAQ:AQST) Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 91,343 shares of Aquestive Therapeutics stock in a transaction on Friday, September 26th. The shares were sold at an average price of $6.03, for a total value of $550,798.29. Following the sale, the chief executive officer directly owned 923,430 shares of the company’s stock, valued at approximately $5,568,282.90. The trade was a 9.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Daniel Barber also recently made the following trade(s):

• On Friday, September 19th, Daniel Barber sold 400 shares of Aquestive Therapeutics stock. The shares were sold at an average price of $6.00, for a total value of $2,400.00.

Aquestive Therapeutics Price Performance

AQST traded down $0.34 during trading on Monday, reaching $5.65. 3,783,104 shares of the stock traded hands, compared to its average volume of 1,807,882. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.12 and a fifty-two week high of $6.43. The stock’s 50-day simple moving average is $4.37 and its two-hundred day simple moving average is $3.50. The stock has a market cap of $563.42 million, a price-to-earnings ratio of -8.07 and a beta of 1.82.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AQST. Oppenheimer lifted their price objective on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an “outperform” rating in a research note on Monday, September 8th. Zacks Research raised Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Finally, Lifesci Capital raised Aquestive Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Aquestive Therapeutics has a consensus rating of “Buy” and an average price target of $10.29.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Aquestive Therapeutics by 6.0% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock valued at $156,000 after acquiring an additional 2,649 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after acquiring an additional 4,134 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Aquestive Therapeutics by 16.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company’s stock valued at $106,000 after acquiring an additional 4,557 shares during the last quarter. Bank of Montreal Can raised its position in shares of Aquestive Therapeutics by 31.1% during the 2nd quarter. Bank of Montreal Can now owns 20,052 shares of the company’s stock valued at $66,000 after acquiring an additional 4,752 shares during the last quarter. Finally, Invesco Ltd. raised its position in shares of Aquestive Therapeutics by 10.7% during the 1st quarter. Invesco Ltd. now owns 53,096 shares of the company’s stock valued at $154,000 after acquiring an additional 5,152 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.